Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

CDMO Recipharm Partners with Sato to Manufacture Product for Japanese Market

By Recipharm AB | March 23, 2017

Recipharm, the contract development and manufacturing organization (CDMO), has entered into a long-term agreement with Sato Pharmaceutical Co. for the commercial manufacture and delivery of Emla Patch to Japan.

Sato, based in Tokyo and founded in 1915, provides effective, safe and high quality products. Emla Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato.

Recipharm’s facility in Karlskoga, Sweden, will produce and deliver to Sato. After a successful launch in Japan, it is expected that the annual volumes of Emla Patch to Sato will be a significant addition to the present production at the Karlskoga facility.

Ingela Palmkvist, General Manager at Recipharm in Karlskoga, said: “We first established a business relationship with Sato in 2012 and this new supply agreement extends our partnership further. We are looking forward to the launch in Japan and cooperating with Sato in developing the business, to the benefit of both companies.”

CDMO Recipharm, which employs some 5,000 workers, offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. The company manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies.

Sato Pharmaceuticals has branches in Europe, the U.S., and Canada and focuses on OTC and ethical pharmaceutical products. The company celebrated its 100th anniversary in 2015.

EMLA is licensed to Sato in Japan and its trademark is used under license from AstraZeneca.

(Source: Recipharm)

Related Articles Read More >

Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE